GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.

Zacks Investment Research • 6 hours ago

TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess.

Business Wire • Oct 23, 2026

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentations highlighting BRIUMVI data. Additionally, the abstract is now available for the late-breaking oral presen.

Business Wire • Oct 21, 2026

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.

Zacks Investment Research • Oct 13, 2026

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). For the analysis, individual patient data from the Phase 3 ULTIMATE I/II pivotal trials for BRIUMVI were reweighted to match pub.

Business Wire • Oct 12, 2026

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1 study evaluating azer-cel in patients with primary progressive multiple sclerosis (PPMS), as well as several presentations highlighting BRIUMVI®.

Business Wire • Oct 8, 2026

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders.

PRNewsWire • Sep 28, 2026

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.

MarketBeat • Sep 18, 2026

TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

Investors Business Daily • Sep 16, 2026